India’s Aurobindo has another sterile manufacturing plant cited by FDA

Even has India's Aurobindo expands its sterile and biologics manufacturing elsewhere, plants in India continue to run into issues with the FDA. (FDA)

Regulatory problems are piling up for the sterile manufacturing operations of India’s Aurobindo, which has had another plant cited by the FDA.

The drugmaker in a fiilng today acknowledged (PDF) that an FDA inspection last month at its sterile formulations plant in Pashamylaram, Hyderabad, ended with a Form 483 listing 9 observations.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The company said that it was working to resolve the issues and that none of the observations related to data integrity and none were repeats. But among other problems, the plant was cited for issues that the FDA said could lead to product contamination, reported the Business Standard, which obtained a copy of the Form 483.

The FDA noted the plant was not cleaning equipment regularly and an inspector also found signs of “vermin,” including rodents and insects, in building used for manufacturing, packaging and storage, the newspaper said.

Aurobindo last year received a Form 483 for another sterile manufacturing plant in nearby Bachupally. Those six observations also included problems in procedures that are supposed to prevent microbiological contamination of sterile products.

RELATED: FDA cites Aurobindo sterile plant for contamination concerns

The findings come as the India drugmaker is expanding its biologics and sterile capabilities in the U.S. and Europe. Last year it, acquired four biosimilar products from Visp, Switzerland-based TL Biopharmaceutical and said it was building a manufacturing plant to support the production of those and eight others it has under development.

The company also has several projects going on in the U.S. It had already broken ground on 567,000-square-foot sterile manufacturing facility at its site in New Jersey that would employ up to 500, when last year its announced plans to build a second sterile injectables plant at the site.  

Suggested Articles

Sanofi is working on a succession plan for CEO Olivier Brandicourt, who'll hit mandatory retirement age in 2021.

Gilead CEO John Milligan racked up $26M in 2018 pay, on paper at least, while incoming chief Daniel O'Day is in line for a cool $30M this year.

Novo Nordisk has at least four more years to build up its newer diabetes drugs before they face Teva's versions of its $2.67B blockbuster Victoza.